SynthesisPloS one2022
The cost of oral cancer: A systematic review.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness of negative-pressure wound therapy in partial-thickness and full-thickness burns: a systematic review.Acta cirurgica brasileira · 2026Pooled it
- Primary Care Referral Delays in Oral Cancer Diagnosis: A Meta-Analysis.Oral diseases · 2025Pooled it
- Automated Detection of Oral Malignant Lesions Using Deep Learning: Scoping Review and Meta-Analysis.Oral diseases · 2025Pooled it
- The economic burden of Chagas disease: A systematic review.PLoS neglected tropical diseases · 2023Pooled it
- Oral Cancer Awareness, Screening Behavior, and Risk-Factor Recognition Among Patients Attending a University Dental Hospital.Healthcare (Basel, Switzerland) · 2026Article
- Changes in gingival cancer: burden of hospitalization and epidemiological evolution from 2001 to 2023 in Spain. a novel approach using hospital activity registry data.BMC oral health · 2026Article
- Plasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis.Scientific reports · 2026Article
- Oral cancer and the impact of glossectomy: challenges and pathways to recovery.Frontiers in oral health · 2026Review
- Hospitalization cost trends for patients with impacted teeth: a double-breakpoint interrupted time series analysis.Frontiers in public health · 2026Article
- CTHRC1/TGF-β/Smad axis serves as therapeutic targets in inhibiting oral squamous cell carcinoma by mediating ferroptosis.Discover oncology · 2025Article
- Article
- Fisetin Inhibits Periodontal Pathogen-Induced EMT in Oral Squamous Cell Carcinoma via the Wnt/β-Catenin Pathway.Nutrients · 2025Article
- Co-development of the educational content of a proposed educational mobile health application prototype on oral cancer using Delphi technique.Scientific reports · 2025Article
- Lip, Oral Cavity, and Pharyngeal Cancers: Global Epidemiology, Risk Factors, and Prevention: A Narrative Review.Health science reports · 2025Article
- Correlation of preoperative 18F-FDG-PET/CT tumor staging and maximum standardized uptake values with preoperative CT, postoperative tumor classification, and histopathological parameters of oral squamous cell carcinoma.Clinical oral investigations · 2025Article
- Perspectives on the Application of Biosensors for the Early Detection of Oral Cancer.Sensors (Basel, Switzerland) · 2025Review
- Socio-demographic disparities in global trends of lip and oral cavity neoplasms from 1990 to 2021.Scientific reports · 2025Article
- Disparities in stage at diagnosis of head and neck tumours in Brazil: a comprehensive analysis of hospital-based cancer registries.Lancet regional health. Americas · 2025Article
- Investigating causal relationship among inflammatory cytokines and oropharyngeal cancer: Mendelian randomization.Discover oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although clinical and epidemiological aspects of oral cancers (OC) are well-documented in the literature, there is a lack of evidence on the economic burden of OC. This study aims to provide a comprehensive systematic assessment on the economic burden of OC based on available evidence worldwide. A systematic review was conducted. The population was any individual, who were exposed to OC, considered here as lip (LC), oral cavity (OCC), or oropharynx (OPC) cancer. The outcome was information on direct (medical and non-medical) and indirect (productivity loss and early death) costs. The data sources included Scopus, Web of Science, Cochrane, BVS, and NHS EED. A search of grey literature (ISPOR and INAHTA proceedings) and a manual search in the reference lists of the included publications were performed (PROSPERO no. CRD42020172471). We identified 24 studies from 2001 to 2021, distributed by 15 countries, in 4 continents. In some developed western countries, the costs of LC, OCC, and OPC reached an average of Gross Domestic Product per capita of 18%, 75%, and 127%, respectively. Inpatient costs for OC and LC were 968% and 384% higher than those for outpatients, respectively. Advanced cancer staging was more costly (from ~22% to 373%) than the early cancer staging. The economic burden of oral cancer is substantial, though underestimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.